Harold Moses
Faculty Member
Last active: 4/25/2016

  1. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A (2017) Clin Cancer Res 23(13): 3371-3384
    › Primary publication · 28003307 (PubMed) · PMC5479746 (PubMed Central)
  2. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE (2017) Mol Oncol 11(4): 405-421
    › Primary publication · 28188683 (PubMed) · PMC5378659 (PubMed Central)
  3. TβRIII Expression in Human Breast Cancer Stroma and the Role of Soluble TβRIII in Breast Cancer Associated Fibroblasts. Jovanović B, Pickup MW, Chytil A, Gorska AE, Johnson KC, Moses HL, Owens P (2016) Cancers (Basel) 8(11)
    › Primary publication · 27827906 (PubMed) · PMC5126760 (PubMed Central)
  4. The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model. Ampuja M, Alarmo EL, Owens P, Havunen R, Gorska AE, Moses HL, Kallioniemi A (2016) Cancer Lett 375(2): 238-244
    › Primary publication · 26970275 (PubMed)
  5. The Discovery and Early Days of TGF-β: A Historical Perspective. Moses HL, Roberts AB, Derynck R (2016) Cold Spring Harb Perspect Biol 8(7)
    › Primary publication · 27328871 (PubMed) · PMC4930926 (PubMed Central)
  6. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) PLoS One 11(6): e0157368
    › Primary publication · 27310713 (PubMed) · PMC4911051 (PubMed Central)
  7. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM (2016) Nat Med 22(5): 497-505
    › Primary publication · 27089513 (PubMed) · PMC4860133 (PubMed Central)
  8. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss. Jolly LA, Novitskiy S, Owens P, Massoll N, Cheng N, Fang W, Moses HL, Franco AT (2016) Cancer Res 76(7): 1804-13
    › Primary publication · 26818109 (PubMed) · PMC4873339 (PubMed Central)
  9. Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma. Hover LD, Owens P, Munden AL, Wang J, Chambless LB, Hopkins CR, Hong CC, Moses HL, Abel TW (2016) Neuro Oncol 18(7): 928-38
    › Primary publication · 26683138 (PubMed) · PMC4896540 (PubMed Central)
  10. Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine. Lyman GH, Moses HL (2016) N Engl J Med 375(1): 4-6
    › Primary publication · 27353537 (PubMed)